An End-to-End Enabler of Biologic Innovation
Abstract: As the biopharma landscape grows more complex, Catalent works to ease the challenges of biologics development for its partners. By uniting expertise in drug substance, drug product, and bioanalytics with proven scientific, regulatory, and operational know-how, Catalent helps customers navigate obstacles and bring transformative therapies to patients. In this interview, David McErlane, Group President of Biologics at Catalent, discusses today’s industry challenges and how the company delivers value that extends beyond technical solutions.